SciBase and Skin and Cancer Institute partner to advance AI-driven skin cancer detection in California

"We are very pleased to announce our collaboration with the Skin and Cancer Institute. In addition to the early detection benefits for patients, the partnership means clinicians at several of their California offices will have access to state-of-the-art melanoma detection technology at point-of-care. For SciBase, this means we expand and establish a coast-to-coast reach that provides patients with access to early melanoma detection technology. It also helps introduce Nevisense to more US payers." said Pia Renaudin, Chief Executive Officer of SciBase.

"We are very pleased to announce our collaboration with the Skin and Cancer Institute. In addition to the early detection benefits for patients, the partnership means clinicians at several of their California offices will have access to state-of-the-art melanoma detection technology at point-of-care. For SciBase, this means we expand and establish a coast-to-coast reach that provides patients with access to early melanoma detection technology. It also helps introduce Nevisense to more US payers." said Pia Renaudin, Chief Executive Officer of SciBase.

For more information, please contact:

Pia Renaudin, CEO SciBase
Tel: +46 73 206 98 02
Email: pia.renaudin@scibase.com

Certified Advisor (CA):

Vator Securities
Tel: +46 8 580 065 99
Email: ca@vatorsec.se

About SciBase and Nevisense
SciBase is a global medical technology company headquartered in Stockholm, Sweden, that has developed a unique point of care platform for the non-invasive detection of skin cancer and other skin conditions. SciBase is a pioneer within augmented intelligence, combining artificial intelligence with Electrical Impedance Spectroscopy (EIS) to provide objective information that assists dermatologists and others in clinical decision-making. SciBase's products include Nevisense and Nevisense Go and to date the platform addresses the areas of melanoma detection, non-melanoma skin cancer detection and skin barrier assessment. Nevisense is the only FDA-approved device for the detection of melanoma and the only MDR-approved technology for skin cancer detection in Europe. SciBase's technology is based on more than 20 years of academic research at the Karolinska Institute in Stockholm, Sweden. For more information please visit www.scibase.com.  All press-releases and financial reports can be found here : http://investors.scibase.se/en/pressreleases .

The following files are available for download:

View original content:https://www.prnewswire.co.uk/news-releases/scibase-and-skin-and-cancer-institute-partner-to-advance-ai-driven-skin-cancer-detection-in-california-301990253.html